SHOP APOTHEKE EUROPE N.V.: Exercise of greenshoe option and early termination of stabilisation period

- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA OR JAPAN.- 


SHOP APOTHEKE EUROPE N.V.: Exercise of greenshoe option and early termination of stabilisation period

Venlo/Cologne, 28 October 2016. SHOP APOTHEKE EUROPE N.V. ("SHOP APOTHEKE EUROPE" or the "Company") has been informed by Berenberg as stabilisation manager of the Initial Public Offering ("IPO") that Berenberg today almost fully exercised the greenshoe option relating to up to 535,714 shares, which was granted to the syndicate banks in connection with the IPO, in the volume of 532,019 shares. Upon exercise of the greenshoe option, which was provided by a group of existing shareholders, the free float remains at c. 49% and the stabilisation period is terminated early.

Michael Köhler, CEO of SHOP APOTHEKE EUROPE: "We are very satisfied with the first trading price, which was set at EUR 30.05, and the first two weeks of trading in the stock. The early and almost full exercise of the greenshoe option complements the successful IPO. The stable share performance reflects the long-term interest of our shareholders in the future development of SHOP APOTHEKE EUROPE."

Berenberg and Citigroup acted as Joint Global Coordinators and, together with Commerzbank, as Joint Bookrunners in connection with the IPO. Lilja & Co. served as independent advisor to the management and the owners of SHOP APOTHEKE EUROPE. Parklane Capital acted as Financial Advisor to the shareholders of SHOP APOTHEKE EUROPE.
 

About SHOP APOTHEKE EUROPE
SHOP APOTHEKE EUROPE is one of Continental Europe's leading online pharmacies with a portfolio that focuses on OTC medication and pharmacy-related BPC products. The Company operates online pharmacies in Germany, Austria, France, Belgium, Italy, Spain and the Netherlands. In Germany, TÜV-certified shop-apotheke.com is the market leader in terms of traffic, delivering a broad range of approximately 100,000 original products to about 1.5 million active customers quickly and at a good price. In addition, SHOP APOTHEKE EUROPE provides comprehensive and consistent pharmaceutical services.

SHOP APOTHEKE EUROPE generated over EUR 125 million in revenues in the financial year 2015. Headquartered in Venlo (Netherlands), SHOP APOTHEKE EUROPE also has an administration site for its sales and marketing units in Cologne (Germany).
 

MEDIA CONTACTS

Trade and public media:
Sven Schirmer
Mobile: +49 152 28 50 63 61
Email: presse@shop-apotheke.com

Financial media:
Bettina Fries
Mobile: +49 172 297 62 43
Email: presse@shop-apotheke.com
 

Disclaimer

This announcement does not, and shall not, in any circumstances constitute a public offering, nor an offer to subscribe any securities in any jurisdiction. The offering was made only on the basis of the securities prospectus issued by the Company in connection with the offering. The shares have already been sold.

This communication is not for publication or distribution, directly or indirectly, in or into the United States, Canada, Australia or Japan. This communication does not constitute or form part of an offer of securities for sale or solicitation of an offer to purchase securities in the United States, Canada, Australia, Japan or in any other jurisdiction in which such offer may be restricted. The securities referred to in this communication have not been, and will not be, registered under the US Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States, except on the basis of an applicable exemption from the registration requirements or in a transaction not subject to the registration requirements of the Securities Act. There will be no public offering of securities in the United States.

In the United Kingdom, this communication is directed only at persons who: (i) are qualified investors within the meaning of the Financial Services and Markets Act 2000 (as amended) and any relevant implementing measures and/or (ii) are outside the United Kingdom or (iii) have professional experience in matters relating to investments and fall within the definition of "investment professionals" contained in article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the "Order") or are persons falling within article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc.) of the Order, or fall within another exemption to the Order (all such persons referred to in (i) to (iii) above together being referred to as "Relevant Persons"). Any person who is not a Relevant Person must not act or rely on this communication or any of its contents. Any investment or investment activity to which this communication relates is available only to Relevant Persons and will be engaged in only with Relevant Persons.

This communication contains statements related to future business and financial performance and future events or developments involving SHOP APOTHEKE EUROPE that may constitute forward-looking statements.
These statements may be identified by words such as "expect", "intend", "look forward to", "believe", "will" or other words of similar meaning. Such statements are based on current expectations and certain assumptions of SHOP APOTHEKE EUROPE's management, of which many are out of our control. These are subjects to a number of risks and uncertainties. Should one or more of this risks or uncertainties materialize, or should underlying expectations not occur or assumptions prove incorrect, actual results, performance or achievements of SHOP APOTHEKE EUROPE may (negatively or positively) vary materially from those described explicitly or implicitly in the relevant forward-looking statement. SHOP APOTHEKE EUROPE does not intend or assume any obligation to update or revise these forward-looking statements in light of developments which differ from those anticipated.